Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study

Completed

Conditions studied: Multiple Sclerosis, Relapsing-remitting

In brief

* To examine short- and long-term value of appearance of new active lesions in predicting extent of cortical and subcortical deep gray matter (SDGM) atrophy over 5 years in ASA (Avonex- Steroid-Azathioprine)study. * To explore how accumulation of cortical and SDGM atrophy over 5 years differs with respect to the number of new active lesions or amount of disease activity, in early relapsing-remitting multiple sclerosis (RRMS) patients who did or did not develop sustained disability progression. * To examine the relationship between development of cortical and SDGM atrophy and regional likelihood of development of new active lesions over 5 years.

Key facts

Study ID

NCT01628315

Run by

University at Buffalo

People needed

159

Starts

2009-03-01

Expected to finish

2014-12-01

Last updated by the study team

2016-02-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Enrolled into the 2-year, double-blind, placebo-controlled ASA study and entered 3 year extension study
• MRI was performed on all patients using a 1.5 T magnet

You may not qualify if…

• MRI images unable to be processed
• All 5 MRI time points not collected

Where it is running

• Buffalo Neuroimaging Analysis Center — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.